Stryker Corp Stock Price, News & Analysis

Stryker (NYSE:SYK), a leading medical technology company, announced its participation in the upcoming 2025 Wells Fargo Securities Healthcare Conference. The event will take place at the Encore Boston Harbor on September 4, 2025.

Andy Pierce, Group President of MedSurg and Neurotechnology, and Jason Beach, Vice President of Finance and Investor Relations, will engage in a Fireside Chat at 2:15 PM ET. Investors can access both the live webcast and replay through Stryker's website.

Stryker (NYSE:SYK) has announced a quarterly dividend declaration of $0.84 per share. The dividend will be paid on October 31, 2025, to shareholders of record as of September 30, 2025. This dividend represents a 5.0% increase compared to the previous year, while remaining consistent with the last quarter's payout.

Stryker (NYSE:SYK) reported strong Q2 2025 results with net sales increasing 11.1% to $6.0 billion. The company achieved significant organic growth of 10.2%, driven by a 9.7% increase in unit volume and 0.5% from higher prices. Adjusted EPS grew 11.4% to $3.13, while adjusted operating income margin improved 110 basis points to 25.7%.

The MedSurg and Neurotechnology segment led growth with 17.3% increased sales to $3.8 billion, while Orthopaedics segment sales grew 2.0% to $2.2 billion. Based on strong performance, Stryker raised its 2025 guidance, now expecting organic net sales growth of 9.5% to 10.0% and adjusted EPS of $13.40 to $13.60.

Inari Medical, a division of Stryker (NYSE:SYK), has launched the next-generation InThrill® Thrombectomy System, marking a significant advancement in small vessel and arteriovenous (AV) access thrombectomy procedures.

The new 8 French over-the-wire system features enhanced capabilities including increased radial force for better luminal wall apposition, offset single open mouth for optimized clot capture, internal struts for even clot distribution, and improved ergonomics. The first commercial case was successfully performed on May 19, 2025, at UPMC health care system by Dr. Joshua Pinter and Dr. Anish Ghodadra.

Stryker (NYSE:SYK) has scheduled its second quarter 2025 financial results announcement for Thursday, July 31, 2025. The company will release its Q2 2025 earnings press release at approximately 4:05 p.m. ET, followed by a webcast discussion at 4:30 p.m. ET. The webcast will be accessible through Stryker's Events & Presentations webpage, with an archive available two hours after the live call concludes.

Stryker (NYSE:SYK) has received FDA 510(k) clearance for its Incompass® Total Ankle System, designed for patients with severe ankle joint conditions. The system integrates technologies from Stryker's Inbone® and Infinity® systems into a comprehensive solution for total ankle replacement.

The innovative platform incorporates Adaptis® Boney Ingrowth Technology and is informed by data from over 85,000 CT scans and 100,000 clinical cases. Built using the SOMA platform and Prophecy Surgical Planning System, Incompass features redesigned instrumentation, improved alignment systems, and streamlined surgical workflow to enhance procedural efficiency and patient-specific care.

Stryker (NYSE:SYK) has received FDA 510(k) clearance for its OptaBlate basivertebral nerve ablation system (OptaBlate BVN), designed to treat chronic vertebrogenic low back pain. The system represents a minimally invasive solution that targets the basivertebral nerve for long-lasting pain relief. Key features include achieving a 1 cm lesion in 7 minutes, steerable curved introducer, microinfusion technology for hydration, and 10-gauge access tools. This addition expands Stryker's pain management portfolio, combining their expertise in radiofrequency ablation technology and vertebral access. The system will be showcased at the American Society of Pain & Neuroscience Annual Meeting in Miami, FL, July 17-20.

Stryker (NYSE:SYK) has announced its quarterly dividend declaration of $0.84 per share. The dividend will be payable on July 31, 2025, to shareholders of record as of June 30, 2025. This dividend amount represents a 5.0% increase compared to the previous year while remaining unchanged from the last quarter's distribution.

Stryker (NYSE:SYK) reported strong Q1 2025 results with reported net sales increasing 11.9% to $5.9 billion and organic net sales growth of 10.1%. The company's MedSurg and Neurotechnology segment saw net sales rise 13.4% to $3.5 billion, while Orthopaedics net sales grew 9.7% to $2.4 billion. Despite reported EPS decreasing 17.6% to $1.69, adjusted EPS increased 13.6% to $2.84. The company raised its full-year 2025 organic net sales growth guidance to 8.5-9.5% and updated adjusted EPS guidance to $13.20-$13.45, accounting for the Inari Medical acquisition dilution and a $200 million tariff impact.